The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era

Por Lwin, Zarnie, Riess, Jonathan W., Gandara, David
Publicado em 2013

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

Por Semrad, Thomas J., Gandara, David R., Lara, Primo N.
Publicado em 2011

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Por Li, Tianhong, Kung, Hsing-Jien, Mack, Philip C., Gandara, David R.
Publicado em 2013

A practical guide of the Southwest Oncology Group (SWOG) to measure malignant pleural mesothelioma (MPM) tumors by RECIST and modified RECIST criteria

Por Tsao, Anne S., Garland, Linda, Redman, Mary, Kernstine, Kemp, Gandara, David, Marom, Edith M.
Publicado em 2011

Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819

Por Redman, Mary W., Crowley, John J., Herbst, Roy S., Hirsch, Fred R., Gandara, David R.
Publicado em 2012

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

Por Holland, William S., Chinn, Danielle C., Lara, Primo N., Gandara, David R., Mack, Philip C.
Publicado no J Cancer Res Clin Oncol (2014)

Non–Small Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

Por Carbone, David P., Gandara, David R., Antonia, Scott J., Zielinski, Christoph, Paz-Ares, Luis
Publicado no J Thorac Oncol (2015)

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

Por Gandara, David R., Hammerman, Peter S., Sos, Martin L., Lara, Primo N., Hirsch, Fred R.
Publicado no Clin Cancer Res (2015)

COMPARISON OF PLATINUM BASED CHEMOTHERAPY IN PATIENTS OLDER AND YOUNGER THAN 70 YEARS OF AGE: AN ANALYSIS OF SOUTHWEST ONCOLOGY GROUP TRIALS 9308 AND 9509

Por Blanchard, Elizabeth M., Moon, James, Hesketh, Paul J., Kelly, Karen, Wozniak, Antoinette J., Crowley, John, Gandara, David
Publicado em 2011

Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

Por Ramalingam, Suresh S., Belani, Chandra P., Ruel, Christopher, Frankel, Paul, Gitlitz, Barbara, Koczywas, Marianna, Espinoza-Delgado, Igor, Gandara, David
Publicado em 2009

Feasibility Study of Intra-patient Sorafenib Dose-Escalation or Re-Escalation in Patients with Previously Treated Advanced Solid Tumors

Por Semrad, Thomas J., Eddings, Courtney, Pan, Chong-Xian, Lau, Derick H., Gandara, David, Beckett, Laurel, Lara, Primo N.
Publicado em 2011

Aberrant Regulation of the MRP3 Gene in Non-Small Cell Lung Carcinoma

Por Mahaffey, Christopher M., Mahaffey, Nichole C., Holland, William, Zhang, Hongqiao, Gandara, David R., Mack, Philip C., Forman, Henry Jay
Publicado em 2012

Chip-based nLC-TOF-MS is a highly stable technology for large scale high-throughput analyses

Por Ruhaak, L. Renee, Taylor, Sandra L., Miyamoto, Suzanne, Kelly, Karen, Leiserowitz, Gary S., Gandara, David, Lebrilla, Carlito B., Kim, Kyoungmi
Publicado em 2013

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

Por Morgan, Robert J., Leong, Lucille, Chow, Warren, Gandara, David, Frankel, Paul, Garcia, Agustin, Lenz, Heinz-Josef, Doroshow, James H.
Publicado em 2010

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Por Iqbal, Syma, Lenz, Heinz-Josef, Gandara, David R., Shibata, Stephen I., Groshen, Susan, Synold, Timothy W., Newman, Edward M.
Publicado em 2013

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

Por Holland, William S., Tepper, Clifford G., Pietri, Jose E., Chinn, Danielle C., Gandara, David R., Mack, Philip C., Lara, Primo N.
Publicado no Cancer Chemother Pharmacol (2011)

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group study (S0339)

Por Davies, Angela M., Chansky, Kari, Lara, Primo N., Gumerlock, Paul H., Crowley, John, Albain, Kathy S., Vogel, Stanley J., Gandara, David R.
Publicado em 2009

Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer

Por Chen, Gigi, Huynh, Minh, Fehrenbacher, Lou, West, Howard, Lara, Primo N., Yavorkovsky, Leonid L., Russin, Michael, Goldstein, Desiree, Gandara, David, Lau, Derick
Publicado em 2009

Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

Por Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Publicado em 2010

Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Por Twardowski, Przemyslaw, Stadler, Walter M, Frankel, Paul, Lara, Primo N, Ruel, Christopher, Chatta, Gurkamal, Heath, Elisabeth, Quinn, David I, Gandara, David R
Publicado em 2010